Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2016, Article ID 6509809, 22 pages
http://dx.doi.org/10.1155/2016/6509809
Review Article

Medical Management of Glaucoma in the 21st Century from a Canadian Perspective

1Université de Montréal, Montreal, QC, Canada
2University of Toronto, Toronto, ON, Canada
3University of Calgary, Calgary, AB, Canada
4Western University, London, ON, Canada
5Queen’s University, Kingston, ON, Canada
6Dalhousie University, Halifax, NS, Canada
7SNELL Medical Communication Inc., Montreal, QC, Canada

Received 18 May 2016; Accepted 19 September 2016

Academic Editor: Vicente Zanon-Moreno

Copyright © 2016 Paul Harasymowycz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye,” Canadian Journal of Ophthalmology, vol. 44, supplement 1, pp. S7–S93, 2009. View at Publisher · View at Google Scholar
  2. F. A. Medeiros, R. Lisboa, R. N. Weinreb, J. M. Liebmann, C. Girkin, and L. M. Zangwill, “Retinal ganglion cell count estimates associated with early development of visual field defects in glaucoma,” Ophthalmology, vol. 120, no. 4, pp. 736–744, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. European Glaucoma Society, Terminology and Guidelines for Glaucoma, 4th edition, 2015, http://www.eugs.org/eng/EGS_guidelines4.asp.
  4. N. Gupta and Y. H. Yücel, “Glaucoma as a neurodegenerative disease,” Current Opinion in Ophthalmology, vol. 18, no. 2, pp. 110–114, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. J. H. Na, K. Lee, J. R. Lee, S. Baek, S. J. Yoo, and M. S. Kook, “Detection of macular ganglion cell loss in preperimetric glaucoma patients with localized retinal nerve fibre defects by spectral-domain optical coherence tomography,” Clinical and Experimental Ophthalmology, vol. 41, no. 9, pp. 870–880, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Lisboa, M. T. Leite, L. M. Zangwill, A. Tafreshi, R. N. Weinreb, and F. A. Medeiros, “Diagnosing preperimetric glaucoma with spectral domain optical coherence tomography,” Ophthalmology, vol. 119, no. 11, pp. 2261–2269, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Singh and D. S. Greenfield, “PPG: to treat or not to treat,” Ophthalmology Times, April 2011, http://ophthalmologytimes.modernmedicine.com/news/ppg-treat-or-not-treat?page=full.
  8. U. Schlötzer-Schrehardt, F. Pasutto, P. Sommer et al., “Genotype-correlated expression of lysyl oxidase-like 1 in ocular tissues of patients with pseudoexfoliation syndrome/glaucoma and normal patients,” The American Journal of Pathology, vol. 173, no. 6, pp. 1724–1735, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Gemenetzi, Y. Yang, and A. J. Lotery, “Current concepts on primary open-angle glaucoma genetics: a contribution to disease pathophysiology and future treatment,” Eye, vol. 26, no. 3, pp. 355–369, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Kumar, M. G. Basavaraj, S. K. Gupta et al., “Role of CYP1B1, MYOC, OPTN and OPTC genes in adult-onset primary open-angle glaucoma: predominance of CYP1B1 mutations in Indian patients,” Molecular Vision, vol. 13, pp. 667–676, 2007. View at Google Scholar · View at Scopus
  11. A. V. Mantravadi and N. Vadhar, “Glaucoma,” Primary Care: Clinics in Office Practice, vol. 42, no. 3, pp. 437–449, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. X.-S. Mi, T.-F. Yuan, and K.-F. So, “The current research status of normal tension glaucoma,” Clinical Interventions in Aging, vol. 9, pp. 1563–1571, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Mroczkowska, A. Benavente-Perez, A. Negi, V. Sung, S. R. Patel, and D. Gherghel, “Primary open-angle glaucoma vs normal-tension glaucoma: the vascular perspective,” JAMA Ophthalmology, vol. 131, no. 1, pp. 36–43, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. R. C. Mudumbai, “Clinical update on normal tension glaucoma,” Seminars in Ophthalmology, vol. 28, no. 3, pp. 173–179, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. B. J. Song and J. Caprioli, “New directions in the treatment of normal tension glaucoma,” Indian Journal of Ophthalmology, vol. 62, no. 5, pp. 529–537, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. A. A. Ghanem, A. M. Elewa, and L. F. Arafa, “Endothelin-1 and nitric oxide levels in patients with glaucoma,” Ophthalmic Research, vol. 46, no. 2, pp. 98–102, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Galassi, B. Giambene, and R. Varriale, “Systemic vascular dysregulation and retrobulbar hemodynamics in normal-tension glaucoma,” Investigative Ophthalmology & Visual Science, vol. 52, no. 7, pp. 4467–4471, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. F. H. Grus, S. C. Joachim, E. M. Hoffmann, and N. Pfeiffer, “Complex autoantibody repertoires in patients with glaucoma,” Molecular Vision, vol. 10, pp. 132–137, 2004. View at Google Scholar · View at Scopus
  19. M. B. Wax, D. A. Barrett, and A. Pestronk, “Increased incidence of paraproteinemia and autoantibodies in patients with normal-pressure glaucoma,” American Journal of Ophthalmology, vol. 117, no. 5, pp. 561–568, 1994. View at Publisher · View at Google Scholar · View at Scopus
  20. J. P. Berdahl, M. P. Fautsch, S. S. Stinnett, and R. R. Allingham, “Intracranial pressure in primary open angle glaucoma, normal tension glaucoma, and ocular hypertension: a case-control study,” Investigative Ophthalmology & Visual Science, vol. 49, no. 12, pp. 5412–5418, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Mroczkowska, A. Ekart, V. Sung et al., “Coexistence of macro- and micro-vascular abnormalities in newly diagnosed normal tension glaucoma patients,” Acta Ophthalmologica, vol. 90, no. 7, pp. e553–e559, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Sergi, D. E. Salerno, M. Rizzi et al., “Prevalence of normal tension glaucoma in obstructive sleep apnea syndrome patients,” Journal of Glaucoma, vol. 16, no. 1, pp. 42–46, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Wright, M. A. Tawfik, M. Waisbourd, and L. J. Katz, “Primary angle-closure glaucoma: an update,” Acta Ophthalmologica, vol. 94, no. 3, pp. 217–225, 2016. View at Publisher · View at Google Scholar
  24. H. A. Quigley and A. T. Broman, “The number of people with glaucoma worldwide in 2010 and 2020,” British Journal of Ophthalmology, vol. 90, no. 3, pp. 262–267, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. H. A. Quigley, D. S. Friedman, and N. G. Congdon, “Possible mechanisms of primary angle-closure and malignant glaucoma,” Journal of Glaucoma, vol. 12, no. 2, pp. 167–180, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. A. D. Filho, S. Cronemberger, R. V. Mérula, and N. Calixto, “Plateau iris,” Arquivos Brasileiros de Oftalmologia, vol. 71, no. 5, pp. 752–758, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Tarongoy, C. L. Ho, and D. S. Walton, “Angle-closure glaucoma: the role of the lens in the pathogenesis, prevention, and treatment,” Survey of Ophthalmology, vol. 54, no. 2, pp. 211–225, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. C. J. Pavlin, K. Harasiewicz, M. D. Sherar, and F. S. Foster, “Clinical use of ultrasound biomicroscopy,” Ophthalmology, vol. 98, no. 3, pp. 287–295, 1991. View at Publisher · View at Google Scholar · View at Scopus
  29. Y.-C. Tham, X. Li, T. Y. Wong, H. A. Quigley, T. Aung, and C.-Y. Cheng, “Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis,” Ophthalmology, vol. 121, no. 11, pp. 2081–2090, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Cook and P. Foster, “Epidemiology of glaucoma: What's new?” Canadian Journal of Ophthalmology, vol. 47, no. 3, pp. 223–226, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. M. Buys, “The need for ‘made in Canada’ glaucoma epidemiology data,” Canadian Journal of Ophthalmology, vol. 46, no. 4, pp. 300–302, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Anraku, Y.-P. Jin, Z. Butty et al., “The Toronto epidemiology glaucoma survey: a pilot study,” Canadian Journal of Ophthalmology, vol. 46, no. 4, pp. 352–357, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. A. V. Perruccio, E. M. Badley, and G. E. Trope, “Self-reported glaucoma in Canada: findings from population-based surveys, 1994–2003,” Canadian Journal of Ophthalmology, vol. 42, no. 2, pp. 219–226, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. M. Buys, R. Gaspo, and K. Kwok, “Referral source, symptoms, and severity at diagnosis of ocular hypertension or open-angle glaucoma in various practices,” Canadian Journal of Ophthalmology, vol. 47, no. 3, pp. 217–222, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. M. Buys and Y.-P. Jin, “Socioeconomic status as a risk factor for late presentation of glaucoma in Canada,” Canadian Journal of Ophthalmology, vol. 48, no. 2, pp. 83–87, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. P. P. Chen, “Blindness in patients with treated open-angle glaucoma,” Ophthalmology, vol. 110, no. 4, pp. 726–733, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. P. P. Lee, J. G. Walt, J. J. Doyle et al., “A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma,” Archives of Ophthalmology, vol. 124, no. 1, pp. 12–19, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. T. R. Einarson, C. Vicente, M. Machado, D. Covert, G. E. Trope, and M. Iskedjian, “Screening for glaucoma in Canada: a systematic review of the literature,” Canadian Journal of Ophthalmology, vol. 41, no. 6, pp. 709–721, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. J. M. Burr, G. Mowatt, R. Hernández et al., “The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation,” Health Technology Assessment, vol. 11, no. 41, 2007. View at Google Scholar · View at Scopus
  40. F. Kassam, K. Yogesan, E. Sogbesan, L. R. Pasquale, and K. F. Damji, “Teleglaucoma: improving access and efficiency for glaucoma care,” Middle East African Journal of Ophthalmology, vol. 20, no. 2, pp. 142–149, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Hollands, D. Johnson, S. Hollands, D. L. Simel, D. Jinapriya, and S. Sharma, “Do findings on routine examination identify patients at risk for primary open-angle glaucoma? The rational clinical examination systematic review,” Journal of the American Medical Association, vol. 309, no. 19, pp. 2035–2042, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. J. M. Cross, C. A. Girkin, C. Owsley, and G. McGwin Jr., “The association between thyroid problems and glaucoma,” British Journal of Ophthalmology, vol. 92, no. 11, pp. 1503–1505, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Varma, P. P. Lee, I. Goldberg, and S. Kotak, “An assessment of the health and economic burdens of glaucoma,” American Journal of Ophthalmology, vol. 152, no. 4, pp. 515–522, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. S. A. Haymes, R. P. Leblanc, M. T. Nicolela, L. A. Chiasson, and B. C. Chauhan, “Risk of falls and motor vehicle collisions in glaucoma,” Investigative Ophthalmology and Visual Science, vol. 48, no. 3, pp. 1149–1155, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Skalicky and I. Goldberg, “Depression and quality of life in patients with glaucoma: a cross-sectional analysis using the geriatric depression scale-15, assessment of function related to vision, and the glaucoma quality of life-15,” Journal of Glaucoma, vol. 17, no. 7, pp. 546–551, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. R. McKean-Cowdin, R. Varma, J. Wu, R. D. Hays, and S. P. Azen, “Severity of visual field loss and health-related quality of life,” American Journal of Ophthalmology, vol. 143, no. 6, pp. 1013–1023, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Q. Rahman, S. M. Beard, R. Discombe, R. Sharma, and D. M. I. Montgomery, “Direct healthcare costs of glaucoma treatment,” British Journal of Ophthalmology, vol. 97, no. 6, pp. 720–724, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. C. E. Traverso, J. G. Walt, S. P. Kelly et al., “Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe,” British Journal of Ophthalmology, vol. 89, no. 10, pp. 1245–1249, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. D. B. Rein, P. Zhang, K. E. Wirth et al., “The economic burden of major adult visual disorders in the United States,” Archives of Ophthalmology, vol. 124, no. 12, pp. 1754–1760, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. Kitazawa and T. Horie, “Diurnal variation of intraocular pressure in primary open-angle glaucoma,” American Journal of Ophthalmology, vol. 79, no. 4, pp. 557–566, 1975. View at Publisher · View at Google Scholar · View at Scopus
  51. F. W. Newell and A. E. Krill, “Diurnal tonography in normal and glaucomatous eyes,” Transactions of the American Ophthalmological Society, vol. 62, pp. 349–374, 1964. View at Google Scholar · View at Scopus
  52. T. Realini, N. Weinreb, and S. Wisniewski, “Short-term repeatability of diurnal intraocular pressure patterns in glaucomatous individuals,” Ophthalmology, vol. 118, no. 1, pp. 47–51, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. R. Lee, M. S. Kook, S. G. Joe et al., “Circadian (24-hour) pattern of intraocular pressure and visual field damage in eyes with normal-tension glaucoma,” Investigative Ophthalmology & Visual Science, vol. 53, no. 2, pp. 881–887, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. E. Renard, K. Palombi, C. Gronfier et al., “Twenty-four hour (Nyctohemeral) rhythm of intraocular pressure and ocular perfusion pressure in normal-tension glaucoma,” Investigative Ophthalmology and Visual Science, vol. 51, no. 2, pp. 882–889, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Kent, IOP: Managing the fluctuation factor variations in intraocular pressure are proving to be more unpredictable than previously believed, Review of Ophthalmology, http://www.reviewofophthalmology.com/content/i/1533/c/28662.
  56. R. Susanna Jr., C. G. De Moraes, G. A. Cioffi, and R. Ritch, “Why do people (still) go blind from glaucoma?” Translational Vision Science and Technology, vol. 4, no. 2, p. 1, 2015. View at Publisher · View at Google Scholar
  57. M. Hatanaka, M. Babic, and R. Susanna Jr., “Reproducibility of the mean, fluctuation, and IOP peak in the diurnal tension curve,” Journal of Glaucoma, vol. 22, no. 5, pp. 390–392, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. I. Tajunisah, S. C. Reddy, and J. Fathilah, “Diurnal variation of intraocular pressure in suspected glaucoma patients and their outcome,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 245, no. 12, pp. 1851–1857, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. S. N. Kletke, D. K. Varma, A. S. Rai, and I. K. Ahmed, Proportion of Undetected Narrow Angles or Angle Closure in Cataract Surgery Referrals, ASCRS & ASOA, 2014, https://ascrs.confex.com/ascrs/14am/webprogram/Paper4839.html.
  60. M. Baskaran, J. V. Iyer, A. K. Narayanaswamy et al., “Anterior segment imaging predicts incident gonioscopic angle closure,” Ophthalmology, vol. 122, no. 12, pp. 2380–2384, 2015. View at Publisher · View at Google Scholar · View at Scopus
  61. G. Vizzeri, R. N. Weinreb, J. M. Martinez de la Casa et al., “Clinicians agreement in establishing glaucomatous progression using the Heidelberg retina tomograph,” Ophthalmology, vol. 116, no. 1, pp. 14–24, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. F. Larocca, A.-H. Dhalla, M. P. Kelly, S. Farsiu, and J. A. Izatt, “Optimization of confocal scanning laser ophthalmoscope design,” Journal of Biomedical Optics, vol. 18, no. 7, Article ID 076015, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. C. Alexandrescu, A. M. Dascalu, A. Panca et al., “Confocal scanning laser ophthalmoscopy in glaucoma diagnosis and management,” Journal of Medicine and Life, vol. 3, no. 3, pp. 229–234, 2010. View at Google Scholar · View at Scopus
  64. I. I. Bussel, G. Wollstein, and J. S. Schuman, “OCT for glaucoma diagnosis, screening and detection of glaucoma progression,” British Journal of Ophthalmology, vol. 98, supplement 2, pp. ii15–ii19, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. P. V. Le, O. Tan, V. Chopra et al., “Regional correlation among ganglion cell complex, nerve fiber layer, and visual field loss in glaucoma,” Investigative Ophthalmology and Visual Science, vol. 54, no. 6, pp. 4287–4295, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. J. M. Wessel, F. K. Horn, R. P. Tornow et al., “Longitudinal analysis of progression in glaucoma using spectral-domain optical coherence tomography,” Investigative Ophthalmology & Visual Science, vol. 54, no. 5, pp. 3613–3620, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. F. A. Medeiros, L. M. Zangwill, C. Bowd, K. Mansouri, and R. N. Weinreb, “The structure and function relationship in glaucoma: implications for detection of progression and measurement of rates of change,” Investigative Ophthalmology and Visual Science, vol. 53, no. 11, pp. 6939–6946, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. K. R. Sung, J. H. Sun, J. H. Na, J. Y. Lee, and Y. Lee, “Progression detection capability of macular thickness in advanced glaucomatous eyes,” Ophthalmology, vol. 119, no. 2, pp. 308–313, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. J. R. Vianna, V. M. Danthurebandara, G. P. Sharpe et al., “Importance of normal aging in estimating the rate of glaucomatous neuroretinal rim and retinal nerve fiber layer loss,” Ophthalmology, vol. 122, no. 12, pp. 2392–2398, 2015. View at Publisher · View at Google Scholar · View at Scopus
  70. M. F. Delgado, N. T. A. Nguyen, T. A. Cox et al., “Automated perimetry: a report by the american academy of ophthalmology,” Ophthalmology, vol. 109, no. 12, pp. 2362–2374, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. F. A. Medeiros, P. A. Sample, and R. N. Weinreb, “Frequency doubling technology perimetry abnormalities as predictors of glaucomatous visual field loss,” American Journal of Ophthalmology, vol. 137, no. 5, pp. 863–871, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. J. A. Landers, I. Goldberg, and S. L. Graham, “Detection of early visual field loss in glaucoma using frequency-doubling perimetry and short-wavelength automated perimetry,” Archives of Ophthalmology, vol. 121, no. 12, pp. 1705–1710, 2003. View at Publisher · View at Google Scholar · View at Scopus
  73. I. Traynis, C. G. De Moraes, A. S. Raza, J. M. Liebmann, R. Ritch, and D. C. Hood, “Prevalence and nature of early glaucomatous defects in the central 10° of the visual field,” JAMA Ophthalmology, vol. 132, no. 3, pp. 291–297, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. B. C. Chauhan, D. F. Garway-Heath, F. J. Goñi et al., “Practical recommendations for measuring rates of visual field change in glaucoma,” British Journal of Ophthalmology, vol. 92, no. 4, pp. 569–573, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. L. Quaranta, F. Gandolfo, R. Turano et al., “Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma,” Investigative Ophthalmology and Visual Science, vol. 47, no. 7, pp. 2917–2923, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. R. Ren, J. B. Jonas, G. Tian et al., “Cerebrospinal fluid pressure in glaucoma: a prospective study,” Ophthalmology, vol. 117, no. 2, pp. 259–266, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. J. Caprioli, J. M. de Leon, P. Azarbod et al., “Trabeculectomy can improve long-term visual function in glaucoma,” Ophthalmology, vol. 123, no. 1, pp. 117–128, 2016. View at Publisher · View at Google Scholar · View at Scopus
  78. American Academy of Ophthalmology Glaucoma Panel, “Preferred Practice Pattern® Guidelines,” Primary Open-Angle Glaucoma, http://www.aao.org/ppp.
  79. A. H. Marvasti, A. J. Tatham, L. M. Zangwill et al., “The relationship between visual field index and estimated number of retinal ganglion cells in glaucoma,” PLoS ONE, vol. 8, no. 10, Article ID e76590, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. D. Meira-Freitas, R. Lisboa, A. Tatham et al., “Predicting progression in glaucoma suspects with longitudinal estimates of retinal ganglion cell counts,” Investigative Ophthalmology & Visual Science, vol. 54, no. 6, pp. 4174–4183, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. M. C. Leske, A. Heijl, M. Hussein, B. Bengtsson, L. Hyman, and E. Komaroff, “Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial,” Archives of Ophthalmology, vol. 121, no. 1, pp. 48–56, 2003. View at Publisher · View at Google Scholar · View at Scopus
  82. A. Heijl, M. C. Leske, B. Bengtsson, L. Hyman, B. Bengtsson, and M. Hussein, “Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial,” Archives of Ophthalmology, vol. 120, no. 10, pp. 1268–1279, 2002. View at Publisher · View at Google Scholar · View at Scopus
  83. AGIS Investigators, “The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration,” American Journal of Ophthalmology, vol. 130, no. 4, pp. 429–440, 2000. View at Publisher · View at Google Scholar
  84. J. R. Vianna and B. C. Chauhan, “How to detect progression in glaucoma,” Progress in Brain Research, vol. 221, pp. 135–158, 2015. View at Publisher · View at Google Scholar
  85. B. C. Chauhan, F. S. Mikelberg, P. H. Artes et al., “Canadian glaucoma study: 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change,” Archives of Ophthalmology, vol. 128, no. 10, pp. 1249–1255, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. D. F. Garway-Heath, D. P. Crabb, C. Bunce et al., “Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial,” The Lancet, vol. 385, no. 9975, pp. 1295–1304, 2015. View at Publisher · View at Google Scholar · View at Scopus
  87. O. Eyawo, J. Nachega, P. Lefebvre et al., “Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis,” Clinical Ophthalmology, vol. 3, no. 1, pp. 447–456, 2009. View at Google Scholar · View at Scopus
  88. L. Quaranta, I. Riva, A. Katsanos, I. Floriani, M. Centofanti, and A. G. P. Konstas, “Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure,” Clinical Ophthalmology, vol. 9, pp. 633–643, 2015. View at Publisher · View at Google Scholar · View at Scopus
  89. I. Riva, A. Katsanos, I. Floriani et al., “Long-term 24-hour intraocular pressure control with travoprost monotherapy in patients with primary open-angle glaucoma,” Journal of Glaucoma, vol. 23, no. 8, pp. 535–540, 2014. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Alm, I. Grierson, and M. B. Shields, “Side effects associated with prostaglandin analog therapy,” Survey of Ophthalmology, vol. 53, no. 6, pp. S93–S105, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. M. Shah, G. Lee, D. R. Lefebvre et al., “A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features,” PLoS ONE, vol. 8, no. 5, Article ID e61638, 2013. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Khouri, P. J. Lama, and R. D. Fechtner, “Beta blockers,” in Glaucoma Medical Therapy: Principles and Management, P. A. Netland, Ed., pp. 55–78, Oxford University Press, New York, NY, USA, 2nd edition, 2008. View at Google Scholar
  93. P. J. Lama, “Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment,” American Journal of Ophthalmology, vol. 134, no. 5, pp. 749–760, 2002. View at Publisher · View at Google Scholar · View at Scopus
  94. S. Salpeter, T. Ormiston, and E. Salpeter, “Cardioselective beta-blockers for chronic obstructive pulmonary disease,” Cochrane Database of Systematic Reviews, vol. 19, no. 4, Article ID CD003566, 2005. View at Google Scholar · View at Scopus
  95. A. H. Neufeld, K. A. Zawistowski, E. D. Page, and B. B. Bromberg, “Influences on the density of β-adrenergic receptors in the cornea and iris-ciliary body of the rabbit,” Investigative Ophthalmology and Visual Science, vol. 17, no. 11, pp. 1069–1075, 1978. View at Google Scholar · View at Scopus
  96. P. Samama, R. A. Bond, H. A. Rockman, C. A. Milano, and R. J. Lefkowitz, “Ligand-induced overexpression of a constitutively active β2-adrenergic receptor: pharmacological creation of a phenotype in transgenic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 1, pp. 137–141, 1997. View at Publisher · View at Google Scholar · View at Scopus
  97. P. B. Molinoff and R. D. Aarons, “Effects of drugs on β-adrenergic receptors on human lymphocytes,” Journal of Cardiovascular Pharmacology, vol. 5, supplement 1, pp. S63–S67, 1983. View at Publisher · View at Google Scholar · View at Scopus
  98. G. M. Maclure, “Chronic open angle glaucoma treated with timolol. A four year study,” Transactions of the Ophthalmological Societies of the United Kingdom, vol. 103, part 1, pp. 78–83, 1983. View at Google Scholar · View at Scopus
  99. J. S. Schuman, B. Horwitz, N. T. Choplin, R. David, D. Albracht, and K. Chen, “A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial,” Archives of Ophthalmology, vol. 115, no. 7, pp. 847–852, 1997. View at Publisher · View at Google Scholar · View at Scopus
  100. L. A. Ericson, “Twenty-four hourly variations of the aqueous flow. Examinations with perilimbal suction cup,” Acta Ophthalmologica, vol. 37, supplement 50, pp. 1–95, 1958. View at Google Scholar
  101. S. M. Drance, “The significance of the diurnal tension variations in normal and glaucomatous eyes,” Archives of Ophthalmology, vol. 64, pp. 494–501, 1960. View at Publisher · View at Google Scholar · View at Scopus
  102. S. L. Letchinger, D. Frohlichstein, D. K. Glieser et al., “Can the concentration of timolol or the frequency of its administration be reduced?” Ophthalmology, vol. 100, no. 8, pp. 1259–1262, 1993. View at Publisher · View at Google Scholar · View at Scopus
  103. L. B. Ong, A. T. Liza-Sharmini, L. L. Chieng et al., “The efficacy of timolol in gel-forming solution after morning or evening dosing in Asian glaucomatous patients,” Journal of Ocular Pharmacology and Therapeutics, vol. 21, no. 5, pp. 388–394, 2005. View at Publisher · View at Google Scholar · View at Scopus
  104. S. J. Fudemberg, C. Batiste, and L. J. Katz, “Efficacy, safety, and current applications of brimonidine,” Expert Opinion on Drug Safety, vol. 7, no. 6, pp. 795–799, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. R. van der Valk, C. A. B. Webers, J. S. A. G. Schouten, M. P. Zeegers, F. Hendrikse, and M. H. Prins, “Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials,” Ophthalmology, vol. 112, no. 7, pp. 1177–1185, 2005. View at Publisher · View at Google Scholar · View at Scopus
  106. B. L. Strom, R. Schinnar, A. J. Apter et al., “Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics,” The New England Journal of Medicine, vol. 349, no. 17, pp. 1628–1635, 2003. View at Publisher · View at Google Scholar · View at Scopus
  107. K. K. Johnson, D. L. Green, J. P. Rife, and L. Limon, “Sulfonamide cross-reactivity: fact or fiction?” Annals of Pharmacotherapy, vol. 39, no. 2, pp. 290–301, 2005. View at Publisher · View at Google Scholar · View at Scopus
  108. C. C. Brackett, H. Singh, and J. H. Block, “Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group,” Pharmacotherapy, vol. 24, no. 7, pp. 856–870, 2004. View at Publisher · View at Google Scholar · View at Scopus
  109. National Institute for Health and Care Excellence, NICE guidelines [CG85]: Glaucoma: diagnosis and management, https://www.nice.org.uk/guidance/cg85.
  110. M. A. Kass, D. K. Heuer, E. J. Higginbotham et al., “The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma,” Archives of Ophthalmology, vol. 120, no. 6, pp. 701–713, 2002. View at Publisher · View at Google Scholar · View at Scopus
  111. L. Quaranta, E. Biagioli, I. Riva et al., “Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis,” Journal of Ocular Pharmacology and Therapeutics, vol. 29, no. 4, pp. 382–389, 2013. View at Publisher · View at Google Scholar · View at Scopus
  112. S. S. Chrai, M. C. Makoid, S. P. Eriksen, and J. R. Robinson, “Drop size and initial dosing frequency problems of topically applied ophthalmic drugs,” Journal of Pharmaceutical Sciences, vol. 63, no. 3, pp. 333–338, 1974. View at Publisher · View at Google Scholar · View at Scopus
  113. G. Holló, F. Topouzis, and R. D. Fechtner, “Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice,” Expert Opinion on Pharmacotherapy, vol. 15, no. 12, pp. 1737–1747, 2014. View at Publisher · View at Google Scholar · View at Scopus
  114. N. Jaenen, C. Baudouin, P. Pouliquen, G. Manni, A. Figueiredo, and T. Zeyen, “Ocular symptoms and signs with preserved and preservative-free glaucoma medications,” European Journal of Ophthalmology, vol. 17, no. 3, pp. 341–349, 2007. View at Google Scholar · View at Scopus
  115. P. J. Pisella, P. Pouliquen, and C. Baudouin, “Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication,” British Journal of Ophthalmology, vol. 86, no. 4, pp. 418–423, 2002. View at Publisher · View at Google Scholar · View at Scopus
  116. C. Boimer and C. M. Birt, “Preservative exposure and surgical outcomes in glaucoma patients: the PESO study,” Journal of Glaucoma, vol. 22, no. 9, pp. 730–735, 2013. View at Publisher · View at Google Scholar · View at Scopus
  117. T. Krupin, J. M. Liebmann, D. S. Greenfield, R. Ritch, and S. Gardiner, “A randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study,” American Journal of Ophthalmology, vol. 151, no. 4, pp. 671–681, 2011. View at Publisher · View at Google Scholar · View at Scopus
  118. L. Quaranta, A. Katsanos, I. Floriani, I. Riva, A. Russo, and A. G. P. Konstas, “Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma,” Journal of Clinical Pharmacology, vol. 52, no. 10, pp. 1552–1557, 2012. View at Publisher · View at Google Scholar · View at Scopus
  119. L. Quaranta, S. Miglior, I. Floriani, T. Pizzolante, and A. G. P. Konstas, “Effects of the timolol-dorzolamide fixed combination and latanoprost on circadian diastolic ocular perfusion pressure in glaucoma,” Investigative Ophthalmology and Visual Science, vol. 49, no. 10, pp. 4226–4231, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. A. G. P. Konstas, L. Quaranta, D. B. Yan et al., “Twenty-four hour efficacy with the dorzolamide/timolol-fixed combination compared with the brimonidine/timolol-fixed combination in primary open-angle glaucoma,” Eye, vol. 26, no. 1, pp. 80–87, 2012. View at Publisher · View at Google Scholar · View at Scopus
  121. T. E. Bournias and J. Lai, “Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs,” Ophthalmology, vol. 116, no. 9, pp. 1719–1724, 2009. View at Publisher · View at Google Scholar · View at Scopus
  122. D. G. Day and D. A. Hollander, “Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension,” Current Medical Research and Opinion, vol. 24, no. 5, pp. 1435–1442, 2008. View at Publisher · View at Google Scholar · View at Scopus
  123. R. Reis, C. F. Queiroz, L. C. Santos, M. P. Avila, and L. Magacho, “A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension,” Clinical Therapeutics, vol. 28, no. 4, pp. 552–559, 2006. View at Publisher · View at Google Scholar · View at Scopus
  124. Q. H. Nguyen, M. G. McMenemy, T. Realini, J. T. Whitson, and S. M. Goode, “Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%,” Journal of Ocular Pharmacology and Therapeutics, vol. 29, no. 3, pp. 290–297, 2013. View at Publisher · View at Google Scholar · View at Scopus
  125. G. Katz, H. DuBiner, J. Samples, S. Vold, and K. Sall, “Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%,” JAMA Ophthalmology, vol. 131, no. 6, pp. 724–730, 2013. View at Publisher · View at Google Scholar · View at Scopus
  126. T. Realini, Q. H. Nguyen, G. Katz, and H. Dubiner, “Fixed-combination brinzolamide 1%/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies,” Eye, vol. 27, no. 7, pp. 841–847, 2013. View at Publisher · View at Google Scholar · View at Scopus
  127. T. Aung, G. Laganovska, T. J. Hernandez Paredes, J. D. Branch, A. Tsorbatzoglou, and I. Goldberg, “Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension,” Ophthalmology, vol. 121, no. 12, pp. 2348–2355, 2014. View at Publisher · View at Google Scholar · View at Scopus
  128. A. Narayanaswamy, A. Neog, M. Baskaran et al., “A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan® in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension,” Indian Journal of Ophthalmology, vol. 55, no. 2, pp. 127–131, 2007. View at Publisher · View at Google Scholar · View at Scopus
  129. M. Y. Kahook, R. D. Fechtner, L. J. Katz, R. J. Noecker, and D. A. Ammar, “A comparison of active ingredients and preservatives between brand name and generic topical glaucoma medications using liquid chromatography-tandem mass spectrometry,” Current Eye Research, vol. 37, no. 2, pp. 101–108, 2012. View at Publisher · View at Google Scholar · View at Scopus
  130. R. G. Fiscella, B. I. Gaynes, and M. Jensen, “Equivalence of generic and brand-name ophthalmic products,” American Journal of Health-System Pharmacy, vol. 58, no. 7, pp. 616–617, 2001. View at Google Scholar · View at Scopus
  131. Z. N. Mammo, J. G. Flanagan, D. F. James, and G. E. Trope, “Generic versus brand-name North American topical glaucoma drops,” Canadian Journal of Ophthalmology, vol. 47, no. 1, pp. 55–61, 2012. View at Publisher · View at Google Scholar · View at Scopus
  132. L. Van Santvliet and A. Ludwig, “Determinants of eye drop size,” Survey of Ophthalmology, vol. 49, no. 2, pp. 197–213, 2004. View at Publisher · View at Google Scholar · View at Scopus
  133. T. Loftsson, P. Jansook, and E. Stefánsson, “Topical drug delivery to the eye: dorzolamide,” Acta Ophthalmologica, vol. 90, no. 7, pp. 603–608, 2012. View at Publisher · View at Google Scholar · View at Scopus
  134. H. Tanihara, T. Inoue, T. Yamamoto, Y. Kuwayama, H. Abe, and M. Araie, “Phase 2 randomized clinical study of a Rho kinase inhibitor, k-115, in primary open-angle glaucoma and ocular hypertension,” American Journal of Ophthalmology, vol. 156, no. 4, pp. 731–e2, 2013. View at Publisher · View at Google Scholar · View at Scopus
  135. H. Tanihara, T. Inoue, T. Yamamoto et al., “Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials,” JAMA Ophthalmology, vol. 133, no. 7, pp. 755–761, 2015. View at Publisher · View at Google Scholar · View at Scopus
  136. H. Tanihara, T. Inoue, T. Yamamoto et al., “One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension,” Acta Ophthalmologica, vol. 94, no. 1, pp. e26–e34, 2016. View at Publisher · View at Google Scholar · View at Scopus
  137. Y. Zhong, Z. Yang, W.-C. Huang, and X. Luo, “Adenosine, adenosine receptors and glaucoma: an updated overview,” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1830, no. 4, pp. 2882–2890, 2013. View at Publisher · View at Google Scholar · View at Scopus
  138. R. Agarwal and P. Agarwal, “Newer targets for modulation of intraocular pressure: focus on adenosine receptor signaling pathways,” Expert Opinion on Therapeutic Targets, vol. 18, no. 5, pp. 527–539, 2014. View at Publisher · View at Google Scholar · View at Scopus
  139. M. O. Karl, K. Peterson-Yantorno, and M. M. Civan, “Cell-specific differential modulation of human trabecular meshwork cells by selective adenosine receptor agonists,” Experimental Eye Research, vol. 84, no. 1, pp. 126–134, 2007. View at Publisher · View at Google Scholar · View at Scopus
  140. C. A. Rasmussen, P. L. Kaufman, R. Ritch, R. Haque, R. K. Brazzell, and J. L. Vittitow, “Latrunculin B reduces intraocular pressure in human ocular hypertension and primary open-angle glaucoma,” Translational Vision Science & Technology, vol. 3, no. 5, article 1, 2014. View at Publisher · View at Google Scholar
  141. J. A. Lusthaus and I. Goldberg, “Emerging drugs to treat glaucoma: targeting prostaglandin F and E receptors,” Expert Opinion on Emerging Drugs, vol. 21, no. 1, pp. 117–128, 2016. View at Publisher · View at Google Scholar
  142. A. Doozandeh and S. Yazdani, “Neuroprotection in glaucoma,” Journal of Ophthalmic and Vision Research, vol. 11, no. 2, pp. 209–220, 2016. View at Publisher · View at Google Scholar
  143. C. S. Tressler, R. Beatty, and M. A. Lemp, “Preservative use in topical glaucoma medications,” Ocular Surface, vol. 9, no. 3, pp. 140–158, 2011. View at Publisher · View at Google Scholar · View at Scopus
  144. R. Noecker and K. V. Miller, “Benzalkonium chloride in glaucoma medications,” Ocular Surface, vol. 9, no. 3, pp. 159–162, 2011. View at Publisher · View at Google Scholar · View at Scopus
  145. P. M. Mathews, P. Y. Ramulu, D. S. Friedman, C. A. Utine, and E. K. Akpek, “Evaluation of ocular surface disease in patients with glaucoma,” Ophthalmology, vol. 120, no. 11, pp. 2241–2248, 2013. View at Publisher · View at Google Scholar · View at Scopus
  146. A. G. P. Konstas, L. Quaranta, and T. Realini, “Overview of the BAK-free travoprost/timolol BAK-free fixed combination,” Expert Opinion on Pharmacotherapy, vol. 13, no. 5, pp. 757–766, 2012. View at Publisher · View at Google Scholar · View at Scopus
  147. R. M. Feldman, A. P. Tanna, R. L. Gross et al., “Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%,” Ophthalmology, vol. 114, no. 7, pp. 1248.e2–1254.e2, 2007. View at Publisher · View at Google Scholar · View at Scopus
  148. D. J. O'Connor, J. F. Martone, and A. Mead, “Additive intraocular pressure lowering effect of various medications with latanoprost,” American Journal of Ophthalmology, vol. 133, no. 6, pp. 836–837, 2002. View at Publisher · View at Google Scholar · View at Scopus
  149. T. D. Realini, “A prospective, randomized, investigator-masked evaluation of the monocular trial in ocular hypertension or open-angle glaucoma,” Ophthalmology, vol. 116, no. 7, pp. 1237–1242, 2009. View at Publisher · View at Google Scholar · View at Scopus
  150. A. M. Bhorade, B. S. Wilson, M. O. Gordon et al., “The utility of the monocular trial: data from the ocular hypertension treatment study,” Ophthalmology, vol. 117, no. 11, pp. 2047–2054, 2010. View at Publisher · View at Google Scholar · View at Scopus
  151. R. Krishna, P. W. DeBry, C. W. Waldman, and P. Koulen, “Comparing the efficacy of the monocular trial treatment paradigm with multiple measurements of intraocular pressure before and after treatment initiation in primary open-angle glaucoma,” Clinical Ophthalmology, vol. 6, no. 1, pp. 491–496, 2012. View at Publisher · View at Google Scholar · View at Scopus
  152. “The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Glaucoma Laser Trial Research Group,” American Journal of Ophthalmology, vol. 120, no. 6, pp. 718–731, 1995.
  153. L. J. Katz, W. C. Steinmann, A. Kabir, J. Molineaux, S. S. Wizov, and G. Marcellino, “Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial,” Journal of Glaucoma, vol. 21, no. 7, pp. 460–468, 2012. View at Publisher · View at Google Scholar · View at Scopus
  154. J. W. Y. Lee, G. S. K. Yau, D. W. F. Yick, and C. Y. F. Yuen, “Micropulse laser trabeculoplasty for the treatment of open-angle glaucoma,” Medicine, vol. 94, no. 49, Article ID e2075, 2015. View at Publisher · View at Google Scholar · View at Scopus
  155. L. M. Brandão and M. C. Grieshaber, “Update on minimally invasive glaucoma surgery (MIGS) and new implants,” Journal of Ophthalmology, vol. 2013, Article ID 705915, 12 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  156. K. Roelofs, S. Arora, and M. W. Dorey, “Implantation of 2 trabecular microbypass stents in a patient with primary open-angle glaucoma refractory to previous glaucoma-filtering surgeries,” Journal of Cataract and Refractive Surgery, vol. 40, no. 8, pp. 1322–1324, 2014. View at Publisher · View at Google Scholar · View at Scopus
  157. M. C. Grieshaber, R. Stegmann, H. R. Grieshaber, and P. Meyer, “Novel device for expanding Schlemm's canal: a morphological study,” British Journal of Ophthalmology, vol. 99, no. 7, pp. 875–877, 2015. View at Publisher · View at Google Scholar · View at Scopus
  158. C. M. G. Olthoff, J. S. A. G. Schouten, B. W. Van De Borne, and C. A. B. Webers, “Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: an evidence-based review,” Ophthalmology, vol. 112, no. 6, pp. 953–961, 2005. View at Publisher · View at Google Scholar · View at Scopus
  159. J. C. Tsai, C. A. McClure, S. E. Ramos, D. G. Schlundt, and J. W. Pichert, “Compliance barriers in glaucoma: a systematic classification,” Journal of Glaucoma, vol. 12, no. 5, pp. 393–398, 2003. View at Publisher · View at Google Scholar · View at Scopus
  160. D. S. Friedman, H. A. Quigley, L. Gelb et al., “Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS),” Investigative Ophthalmology & Visual Science, vol. 48, no. 11, pp. 5052–5057, 2007. View at Publisher · View at Google Scholar · View at Scopus
  161. G. F. Schwartz and H. A. Quigley, “Adherence and persistence with glaucoma therapy,” Survey of Ophthalmology, vol. 53, supplement 1, pp. S57–S68, 2008. View at Publisher · View at Google Scholar · View at Scopus
  162. R. Sayner, D. M. Carpenter, S. J. Blalock et al., “Accuracy of patient-reported adherence to glaucoma medications on a visual analog scale compared with electronic monitors,” Clinical Therapeutics, vol. 37, no. 9, pp. 1975–1985, 2015. View at Publisher · View at Google Scholar · View at Scopus
  163. B. Vrijens and J. Urquhart, “Methods for measuring, enhancing, and accounting for medication adherence in clinical trials,” Clinical Pharmacology and Therapeutics, vol. 95, no. 6, pp. 617–626, 2014. View at Publisher · View at Google Scholar · View at Scopus
  164. P. F. Cook, S. J. Schmiege, S. L. Mansberger, J. Kammer, T. Fitzgerald, and M. Y. Kahook, “Predictors of adherence to glaucoma treatment in a multisite study,” Annals of Behavioral Medicine, vol. 49, no. 1, pp. 29–39, 2015. View at Publisher · View at Google Scholar · View at Scopus
  165. H. Cate, D. Bhattacharya, A. Clark, R. Holland, and D. C. Broadway, “Patterns of adherence behaviour for patients with glaucoma,” Eye, vol. 27, no. 4, pp. 545–553, 2013. View at Publisher · View at Google Scholar · View at Scopus
  166. F. J. Domino, “Improving adherence to treatment for hypertension,” American Family Physician, vol. 71, no. 11, pp. 2089–2090, 2005. View at Google Scholar · View at Scopus
  167. F. Djafari, M. R. Lesk, P. J. Harasymowycz, D. Desjardins, and J. Lachaine, “Determinants of adherence to glaucoma medical therapy in a long-term patient population,” Journal of Glaucoma, vol. 18, no. 3, pp. 238–243, 2009. View at Publisher · View at Google Scholar · View at Scopus
  168. S. C. Loon, J. Jin, and M. Jin Goh, “The relationship between quality of life and adherence to medication in glaucoma patients in Singapore,” Journal of Glaucoma, vol. 24, no. 5, pp. e36–e42, 2015. View at Publisher · View at Google Scholar · View at Scopus
  169. J. E. Stryker, A. D. Beck, S. A. Primo et al., “An exploratory study of factors influencing glaucoma treatment adherence,” Journal of Glaucoma, vol. 19, no. 1, pp. 66–72, 2010. View at Publisher · View at Google Scholar · View at Scopus
  170. S. Kripalani, X. Yao, and R. B. Haynes, “Interventions to enhance medication adherence in chronic medical conditions: a systematic review,” Archives of Internal Medicine, vol. 167, no. 6, pp. 540–550, 2007. View at Publisher · View at Google Scholar · View at Scopus
  171. T. A. Gray, C. Fenerty, R. Harper et al., “Individualised patient care as an adjunct to standard care for promoting adherence to ocular hypotensive therapy: an exploratory randomised controlled trial,” Eye, vol. 26, no. 3, pp. 407–417, 2012. View at Publisher · View at Google Scholar · View at Scopus
  172. H. J. M. Beckers, C. A. B. Webers, M. J. W. M. Busch, H. M. A. Brink, T. P. Colen, and J. S. A. G. Schouten, “Adherence improvement in Dutch glaucoma patients: a randomized controlled trial,” Acta Ophthalmologica, vol. 91, no. 7, pp. 610–618, 2013. View at Publisher · View at Google Scholar · View at Scopus
  173. S. E. Norell, “Improving medication compliance: a randomised clinical trial,” The British Medical Journal, vol. 2, no. 6197, pp. 1031–1033, 1979. View at Publisher · View at Google Scholar · View at Scopus
  174. C. O. Okeke, H. A. Quigley, H. D. Jampel et al., “Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients,” Ophthalmology, vol. 116, no. 12, pp. 2286–2293, 2009. View at Publisher · View at Google Scholar · View at Scopus
  175. B. Sleath, S. J. Blalock, D. M. Carpenter et al., “Ophthalmologist-patient communication, self-efficacy, and glaucoma medication adherence,” Ophthalmology, vol. 122, no. 4, pp. 748–754, 2015. View at Publisher · View at Google Scholar · View at Scopus
  176. L. E. Dreer, C. Owsley, L. Campbell, L. Gao, A. Wood, and C. A. Girkin, “Feasibility, patient acceptability, and preliminary efficacy of a culturally informed, health promotion program to improve glaucoma medication adherence among African Americans: ‘Glaucoma Management Optimism for African Americans Living with Glaucoma’ (GOAL),” Current Eye Research, vol. 41, no. 1, pp. 50–58, 2016. View at Publisher · View at Google Scholar · View at Scopus
  177. T. A. Gray, L. C. Orton, D. Henson, R. Harper, and H. Waterman, “Interventions for improving adherence to ocular hypotensive therapy,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD006132, 2009. View at Google Scholar · View at Scopus
  178. B. Sleath, D. M. Carpenter, S. J. Blalock et al., “Applying the resources and supports in self-management framework to examine ophthalmologist-patient communication and glaucoma medication adherence,” Health Education Research, vol. 30, no. 5, pp. 693–705, 2015. View at Publisher · View at Google Scholar · View at Scopus
  179. O. J. Saeedi, C. Luzuriaga, N. Ellish, and A. Robin, “Potential limitations of e-mail and text messaging in improving adherence in glaucoma and ocular hypertension,” Journal of Glaucoma, vol. 24, no. 5, pp. e95–e102, 2015. View at Publisher · View at Google Scholar · View at Scopus
  180. Glaucoma Research Foundation, “Alternative Therapies for Glaucoma,” http://www.glaucoma.org/treatment/alternative-therapies-for-glaucoma.php.
  181. D. J. Rhee, G. L. Spaeth, J. S. Myers et al., “Prevalence of the use of complementary and alternative medicine for glaucoma,” Ophthalmology, vol. 109, no. 3, pp. 438–443, 2002. View at Publisher · View at Google Scholar · View at Scopus
  182. B. A. Ford, M. Gooi, A. Carlsson, and A. C. Crichton, “Morning dosing of once-daily glaucoma medication is more convenient and may lead to greater adherence than evening dosing,” Journal of Glaucoma, vol. 22, no. 1, pp. 1–4, 2013. View at Publisher · View at Google Scholar · View at Scopus
  183. J. D. Stein, N. Shekhawat, N. Talwar, and R. Balkrishnan, “Impact of the introduction of generic latanoprost on glaucoma medication adherence,” Ophthalmology, vol. 122, no. 4, pp. 738–747, 2015. View at Publisher · View at Google Scholar · View at Scopus
  184. R. Kholdebarin, R. J. Campbell, Y.-P. Jin et al., “Multicenter study of compliance and drop administration in glaucoma,” Canadian Journal of Ophthalmology, vol. 43, no. 4, pp. 454–461, 2008. View at Publisher · View at Google Scholar · View at Scopus